<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="research-article" xml:lang="en" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">World J Surg Oncol</journal-id><journal-id journal-id-type="iso-abbrev">World J Surg Oncol</journal-id><journal-id journal-id-type="pmc-domain-id">199</journal-id><journal-id journal-id-type="pmc-domain">wjsurgonc</journal-id><journal-title-group><journal-title>World Journal of Surgical Oncology</journal-title></journal-title-group><issn pub-type="epub">1477-7819</issn><publisher><publisher-name>BMC</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC10134640</article-id><article-id pub-id-type="pmcid-ver">PMC10134640.1</article-id><article-id pub-id-type="pmcaid">10134640</article-id><article-id pub-id-type="pmcaiid">10134640</article-id><article-id pub-id-type="pmid">37101165</article-id><article-id pub-id-type="doi">10.1186/s12957-023-03015-8</article-id><article-id pub-id-type="publisher-id">3015</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Research</subject></subj-group></article-categories><title-group><article-title>Influence of the initial recurrence site on prognosis after radical surgery for colorectal cancer: a retrospective cohort study</article-title></title-group><contrib-group><contrib contrib-type="author" equal-contrib="yes"><name name-style="western"><surname>Pu</surname><given-names initials="H">Hongjiang</given-names></name><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author" equal-contrib="yes"><name name-style="western"><surname>Chen</surname><given-names initials="Y">Yaxue</given-names></name><xref ref-type="aff" rid="Aff3">3</xref></contrib><contrib contrib-type="author" equal-contrib="yes"><name name-style="western"><surname>Shen</surname><given-names initials="R">Ruoxia</given-names></name><xref ref-type="aff" rid="Aff4">4</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Zhang</surname><given-names initials="Y">Yin</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Yang</surname><given-names initials="D">Duan</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Liu</surname><given-names initials="L">Lizhu</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author" corresp="yes"><name name-style="western"><surname>Dong</surname><given-names initials="X">Xingxiang</given-names></name><address><email>dongxw_621@163.com</email></address><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Yang</surname><given-names initials="G">Guangjun</given-names></name><address><email>ygj350493684@163.com</email></address><xref ref-type="aff" rid="Aff1">1</xref></contrib><aff id="Aff1"><label>1</label>Department of Radiology, the Third Affiliated Hospital of Kunming Medical University, Yunnan Cancer Hospital, Yunnan Cancer Centre, Kunming, 650118 China </aff><aff id="Aff2"><label>2</label><institution-wrap><institution-id institution-id-type="GRID">grid.507934.c</institution-id><institution>Department of Oncology, </institution><institution>Dazhou Central Hospital, </institution></institution-wrap>Dazhou, 635000 Sichuan China </aff><aff id="Aff3"><label>3</label>Department of Nursing, Dazhou Vocational and Technical College, Dazhou, 635000 Sichuan China </aff><aff id="Aff4"><label>4</label>Department of Ultrasound Medicine, The Third Affiliated Hospital of Kunming Medical University, Yunnan Cancer Hospital, Yunnan Cancer Centre, Kunming, 650118 China </aff></contrib-group><pub-date pub-type="epub"><day>27</day><month>4</month><year>2023</year></pub-date><pub-date pub-type="collection"><year>2023</year></pub-date><volume>21</volume><issue-id pub-id-type="pmc-issue-id">424968</issue-id><elocation-id>137</elocation-id><history><date date-type="received"><day>15</day><month>2</month><year>2023</year></date><date date-type="accepted"><day>4</day><month>4</month><year>2023</year></date></history><pub-history><event event-type="pmc-release"><date><day>27</day><month>04</month><year>2023</year></date></event><event event-type="pmc-live"><date><day>28</day><month>04</month><year>2023</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2023-11-01 20:25:19.197"><day>01</day><month>11</month><year>2023</year></date></event></pub-history><permissions><copyright-statement>&#169; The Author(s) 2023</copyright-statement><license><ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p><bold>Open Access</bold>This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>. The Creative Commons Public Domain Dedication waiver (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://creativecommons.org/publicdomain/zero/1.0/">http://creativecommons.org/publicdomain/zero/1.0/</ext-link>) applies to the data made available in this article, unless otherwise stated in a credit line to the data.</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="12957_2023_Article_3015.pdf"/><abstract id="Abs1"><sec><title>Background &amp; Aims</title><p id="Par1">In this retrospective study, we aimed to elucidate how the initial recurrence site influences the post-recurrence survival (PRS) after the curative resection of colorectal cancer.</p></sec><sec><title>Patients and methods</title><p id="Par2">We collected samples from patients with stage I-III colorectal adenocarcinoma who were admitted to Yunnan Cancer Hospital from January 2008 to December 2019. Four hundred and six patients who developed recurrence after radical resection were included. The cases were classified according to the original site of recurrence as follows: liver metastases (<italic toggle="yes">n</italic>&#8201;=&#8201;98), lung metastases (<italic toggle="yes">n</italic>&#8201;=&#8201;127), peritoneum (<italic toggle="yes">n</italic>&#8201;=&#8201;32), other individual organ (<italic toggle="yes">n</italic>&#8201;=&#8201;69), two or more organs or sites (<italic toggle="yes">n</italic>&#8201;=&#8201;49), and local recurrence (<italic toggle="yes">n</italic>&#8201;=&#8201;31). Kaplan&#8211;Meier survival curves were used to compare the PRS of patients with different initial sites of recurrence. The influence of the initial recurrence site on PRS was analyzed using the Cox proportional hazards model.</p></sec><sec><title>Results</title><p id="Par3">The 3-year PRS of simple liver metastasis was 54.04% (95% CI, 45.46%-64.24%), and the 3-year PRS of simple lung metastasis was 50.05% (95% CI, 42.50%-58.95%). No significant difference was observed between simple liver metastasis or simple lung metastasis and local recurrence with a 3-year PRS of 66.99% (95% CI, 53.23%-84.32%). The 3-year PRS for peritoneal metastases was 25.43% (95% CI, 14.76%-43.82%), and the 3-year PRS for two or more organ sites was 34.84% (95% CI, 24.16%-50.24%). The peritoneal (hazard ratio [HR], 1.75; 95% CI, 1.10&#8211;2.79; <italic toggle="yes">P</italic>&#8201;=&#8201;0.0189) and metastasis to two or more organs or sites (HR, 1.59; 95% CI, 1.05&#8211;2.43; <italic toggle="yes">P</italic>&#8201;=&#8201;0.0304) were PRS-independent adverse prognostic factors.</p></sec><sec><title>Conclusion</title><p id="Par4">The prognosis of patients with peritoneum and multiple organs or sites recurred was poor. This study suggests early monitoring of peritoneal and multiple organ or site recurrence after surgery. This part of patients should receive comprehensive treatment as early as possible to improve their prognosis.</p></sec></abstract><kwd-group xml:lang="en"><title>Keywords</title><kwd>Site of initial recurrence</kwd><kwd>Post-recurrence survival</kwd><kwd>Colorectal cancer</kwd><kwd>Prognosis</kwd></kwd-group><funding-group><award-group><funding-source><institution>Yunnan Provincial Department of Education</institution></funding-source><award-id>2020J0208</award-id></award-group></funding-group><funding-group><award-group><funding-source><institution>Yunnan Fundamental Research Projects</institution></funding-source><award-id>grant NO. 202001AY070001-242</award-id></award-group></funding-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#169; The Author(s) 2023</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1"><title>Introduction</title><p id="Par13">The key reason for the increasing mortality of colorectal cancer each year is the recurrence and metastasis of the cancer after radical surgery in some patients [<xref ref-type="bibr" rid="CR1">1</xref>]. Data from our center published previously indicates that 25.10% of patients with stage I-III colorectal cancer experience postoperative recurrence [<xref ref-type="bibr" rid="CR2">2</xref>]. Multiple influencing factors, including histological grade, serum CEA level, tumor location, surgical method, number of positive lymph nodes, and adjuvant chemotherapy, function as independent risk factors for the recurrence and metastasis of colorectal cancer post-surgery [<xref ref-type="bibr" rid="CR3">3</xref>, <xref ref-type="bibr" rid="CR4">4</xref>]. A post-recurrence survival (PRS) of 23.1&#160;months after colorectal cancer recurrence was reported, and the post-recurrence prognosis was found to be poor [<xref ref-type="bibr" rid="CR5">5</xref>]. Older age, advanced pathological stage, rectal tumor, and recurrence are independent risk factors for PRS in colorectal cancer [<xref ref-type="bibr" rid="CR6">6</xref>]. Postoperative recurrence surgery, chemotherapy, and radiotherapy can affect the PRS. The accurate detection of recurrent lesions after the resection of colorectal cancer and appropriate treatment post-recurrence can reduce the mortality of patients with colorectal cancer [<xref ref-type="bibr" rid="CR7">7</xref>, <xref ref-type="bibr" rid="CR8">8</xref>].</p><p id="Par14">Although the duration of survival post recurrence is significantly reduced, in recent years, with the advancement of medical technology, the methods used for oligometastatic therapy have been improved continuously, and currently, patients with post-surgery recurrence have longer survival. However, differences in the site of initial recurrence may still affect patient outcomes. The accurate detection of the site of initial recurrence leading to poor patient outcomes post recurrence is important for treatment. In addition, predicting the prognosis post recurrence is also important for determining the treatment strategy for colorectal cancer. However, a limited number of studies have investigated the effect of the initial site of recurrence on the postoperative prognosis.</p><p id="Par15">In this study, the first recurrence of organ metastases after surgery was categorized based on six initial sites of recurrence, and the impact of each initial recurrence site on the post-recurrence prognosis was analyzed.</p></sec><sec id="Sec2"><title>Patients and methods</title><sec id="Sec3"><title>Ethics statement</title><p id="Par16">This study protocol was reviewed and approved by the Institutional Review Board of Yunnan Cancer Hospital (KY2019141) and conducted in accordance with the principles of the Declaration of Helsinki. Written informed consent was obtained from all patients.</p></sec><sec id="Sec4"><title>Inclusion of patients</title><p id="Par17">The study was conducted in accordance with the requirements of the Reporting Epidemiology for Enhanced Observational Studies (STROBE) Statement: Guidelines for Reporting Observational Studies [<xref ref-type="bibr" rid="CR9">9</xref>]. We included patients with stage I-III colorectal adenocarcinoma undergoing radical surgical resection who were treated at Yunnan Cancer Hospital from March 8, 2010 to May 29, 2018. Four hundred and six patients with postoperative recurrence and a follow-up of more than 3&#160;years were included in this retrospective study. Patients who received preoperative neoadjuvant therapy and had a history of other primary tumors were excluded from this study.</p></sec><sec id="Sec5"><title>Postoperative monitoring and recurrence</title><p id="Par18">Routine blood tumor marker testing and computed tomography (CT) scans of the thoracic and abdominal regions were performed every 3&#8211;6&#160;months after 1&#8211;3&#160;years and every 6&#8211;12&#160;months after 4&#8211;5&#160;years after colorectal cancer resection. When symptoms developed during the follow-up, imaging diagnosis was conducted based on the results of the following tests: positron emission tomography (PET-CT) or bone scintigraphy for bone pain; magnetic resonance imaging (MRI) or CT of the head for neurological symptoms; whole abdomen enhanced CT, abdominal ultrasound, and gastrointestinal endoscopy for abdominal symptoms. If the site of recurrence was identified, cranial MRI or CT and PET-CT or bone scintigraphy was routinely performed. Based on the results of the diagnostic imaging tests, collective diagnosis by a colorectal surgeon, medical oncologist, pathologist, and radiologist was performed to determine the site of recurrence. Needle biopsy was performed on the sites in which recurrence could not be confirmed.</p></sec><sec id="Sec6"><title>Classification of the site of initial recurrence</title><p id="Par19">The site of initial recurrence was defined as the organ of recurrence and could be identified by each diagnostic imaging test performed before treatment for identifying recurrence. The initial metastatic organs were categorized based on six sites of initial recurrence: (1) simple liver metastasis; (2) simple lung metastasis, including metastasis in one or both lungs; (3) peritoneal metastasis (with or without abdominal organ metastasis); (4) metastasis to other individual organs, including an unlimited number of distant lymph nodes, bone, adrenal gland, ovary, uterus, bladder, ureter, abdominal wall, and muscles, among other organs; (5) two or more organs or sites; (6) local recurrence, clear diagnosis by colonoscopy biopsy, and no distant metastasis. Recurrence-free survival (RFS) and PRS were analyzed for patients with and without recurrence. RFS was defined as the survival from surgery to postoperative recurrence or all-cause death for colorectal cancer. PRS was defined as the time from first evidence detection to censored patient relapse to all-cause death in the absence of events in the last observation period.</p></sec><sec id="Sec7"><title>Statistical analysis</title><p id="Par20">Continuous variables were compared between the two groups using the Mann&#8211;Whitney U test. Categorical variables were compared using Fisher's exact test. PRS was analyzed using the Kaplan&#8211;Meier method, and the log-rank test was used for intergroup comparisons. Univariate and multivariate analyses of PRS was performed using the Cox proportional hazards model. The following variables were analyzed: age, gender, body mass index, time to recurrence, initial recurrence site, surgical route, primary tumor location, tumor differentiation, tissue type, pathological T stage, pathological N stage, number of lymph nodes dissected, vessels, neural invasion, tumor deposition, postoperative adjuvant chemotherapy, adjuvant chemotherapy regimen, adjuvant chemotherapy cycle, palliative chemotherapy, preoperative carcinoembryonic antigen (CEA), carcinoma antigen 19&#8211;9 (CA199), and postoperative CEA. Multivariate analysis was performed for all variables with <italic toggle="yes">P</italic> value&#8201;&lt;&#8201;0.05 in the univariate analysis. The analyses were two-sided and conducted using the R software (version 3.6.3; <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.R-project.org">http://www.R-project.org</ext-link>). Statistical significance was set at <italic toggle="yes">P</italic>-value&#8201;&lt;&#8201;0.05.</p></sec></sec><sec id="Sec8"><title>Results</title><p id="Par21">A total of 3599 patients with stage I-III colorectal adenocarcinoma who underwent radical surgery in Yunnan Cancer Hospital from 2008 to 2019 were selected. In strict adherence with the inclusion and exclusion criteria, 406 patients with recurrence after radical resection were enrolled. According to recurrence within 2&#160;years, 252 cases of early recurrence and 154 cases of late recurrence were identified. According to the recurrence pattern, 31 cases of local recurrence, 315 cases of distant metastasis, and 60 cases of simultaneous recurrence were identified. Based on the recurrence site, 98 cases (24.14%) of pure liver metastasis, 127 cases (31.28%) of pure lung metastasis, 32 cases (7.88%) of peritoneal metastasis, 69 cases (17.00%) of metastasis to other individual organs, and 49 cases (12.07%) of metastasis to two or more organ or sites were identified (Fig.&#160;<xref rid="Fig1" ref-type="fig">1</xref>). The median patient age was 60&#160;years (range 21&#8211;87&#160;years). Two hundred and twenty (54.19%) patients were males. The median RFS was 11.90&#160;months (range 0.27&#8211;66.67&#160;months). After at least 3&#160;years of follow-up, 235 (57.88%) patients died (Table <xref rid="Tab1" ref-type="table">1</xref>).<fig id="Fig1" position="float" orientation="portrait"><label>Fig. 1</label><caption><p>Study flow chart</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="MO1" position="float" orientation="portrait" xlink:href="12957_2023_3015_Fig1_HTML.jpg"/></fig><table-wrap id="Tab1" position="float" orientation="portrait"><label>Table 1</label><caption><p>Patient characteristics</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" colspan="1" rowspan="1">Characteristic</th><th align="left" colspan="1" rowspan="1">All (406)</th><th align="left" colspan="1" rowspan="1">No death (171)</th><th align="left" colspan="1" rowspan="1">Death (235)</th><th align="left" colspan="1" rowspan="1"><italic toggle="yes">P</italic>-value</th></tr></thead><tbody><tr><td align="left" colspan="5" rowspan="1">Age (years)</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;Mean (SD)</td><td align="left" colspan="1" rowspan="1">58.72 (12.71)</td><td align="left" colspan="1" rowspan="1">58.11 (12.87)</td><td align="left" colspan="1" rowspan="1">59.17 (12.59)</td><td align="left" rowspan="2" colspan="1">0.408</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;Median (IQR)</td><td align="left" colspan="1" rowspan="1">60.00 (21.00&#8211;87.00)</td><td align="left" colspan="1" rowspan="1">60.00 (21.00&#8211;85.00)</td><td align="left" colspan="1" rowspan="1">61.00 (22.00&#8211;87.00)</td></tr><tr><td align="left" colspan="5" rowspan="1">BMI (kg/m<sup>2</sup>)</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;Mean (SD)</td><td align="left" colspan="1" rowspan="1">22.36 (3.25)</td><td align="left" colspan="1" rowspan="1">22.70 (3.24)</td><td align="left" colspan="1" rowspan="1">22.12 (3.23)</td><td align="left" rowspan="2" colspan="1">0.077</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;Median (IQR)</td><td align="left" colspan="1" rowspan="1">21.89 (13.89&#8211;34.29)</td><td align="left" colspan="1" rowspan="1">22.04 (15.24&#8211;31.60)</td><td align="left" colspan="1" rowspan="1">21.78 (13.89&#8211;34.29)</td></tr><tr><td align="left" colspan="1" rowspan="1">Recurrence group</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">0.005</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;Local recurrence</td><td align="left" colspan="1" rowspan="1">31 (7.64%)</td><td align="left" colspan="1" rowspan="1">19 (11.11%)</td><td align="left" colspan="1" rowspan="1">12 (5.11%)</td><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;Distant metastasis</td><td align="left" colspan="1" rowspan="1">315 (77.59%)</td><td align="left" colspan="1" rowspan="1">136 (79.53%)</td><td align="left" colspan="1" rowspan="1">179 (76.17%)</td><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;Simultaneous recurrence</td><td align="left" colspan="1" rowspan="1">60 (14.78%)</td><td align="left" colspan="1" rowspan="1">16 (9.36%)</td><td align="left" colspan="1" rowspan="1">44 (18.72%)</td><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">Recurrence time</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">0.058</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;Early recurrence</td><td align="left" colspan="1" rowspan="1">252 (62.07%)</td><td align="left" colspan="1" rowspan="1">97 (56.73%)</td><td align="left" colspan="1" rowspan="1">155 (65.96%)</td><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;Late recurrence</td><td align="left" colspan="1" rowspan="1">154 (37.93%)</td><td align="left" colspan="1" rowspan="1">74 (43.27%)</td><td align="left" colspan="1" rowspan="1">80 (34.04%)</td><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">Recurrence site</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">0.013</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;Liver</td><td align="left" colspan="1" rowspan="1">98 (24.14%)</td><td align="left" colspan="1" rowspan="1">47 (27.49%)</td><td align="left" colspan="1" rowspan="1">51 (21.70%)</td><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;Lung</td><td align="left" colspan="1" rowspan="1">127 (31.28%)</td><td align="left" colspan="1" rowspan="1">52 (30.41%)</td><td align="left" colspan="1" rowspan="1">75 (31.91%)</td><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;Peritoneum</td><td align="left" colspan="1" rowspan="1">32 (7.88%)</td><td align="left" colspan="1" rowspan="1">7 (4.09%)</td><td align="left" colspan="1" rowspan="1">25 (10.64%)</td><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;Other individual organ</td><td align="left" colspan="1" rowspan="1">69 (17.00%)</td><td align="left" colspan="1" rowspan="1">31 (18.13%)</td><td align="left" colspan="1" rowspan="1">38 (16.17%)</td><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;Two or more organs or sites</td><td align="left" colspan="1" rowspan="1">49 (12.07%)</td><td align="left" colspan="1" rowspan="1">15 (8.77%)</td><td align="left" colspan="1" rowspan="1">34 (14.47%)</td><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;Local recurrence</td><td align="left" colspan="1" rowspan="1">31 (7.64%)</td><td align="left" colspan="1" rowspan="1">19 (11.11%)</td><td align="left" colspan="1" rowspan="1">12 (5.11%)</td><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">Liver</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">0.179</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;No</td><td align="left" colspan="1" rowspan="1">308 (75.86%)</td><td align="left" colspan="1" rowspan="1">124 (72.51%)</td><td align="left" colspan="1" rowspan="1">184 (78.30%)</td><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;Yes</td><td align="left" colspan="1" rowspan="1">98 (24.14%)</td><td align="left" colspan="1" rowspan="1">47 (27.49%)</td><td align="left" colspan="1" rowspan="1">51 (21.70%)</td><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">Lung</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">0.747</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;No</td><td align="left" colspan="1" rowspan="1">279 (68.72%)</td><td align="left" colspan="1" rowspan="1">119 (69.59%)</td><td align="left" colspan="1" rowspan="1">160 (68.09%)</td><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;Yes</td><td align="left" colspan="1" rowspan="1">127 (31.28%)</td><td align="left" colspan="1" rowspan="1">52 (30.41%)</td><td align="left" colspan="1" rowspan="1">75 (31.91%)</td><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">Peritoneum</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">0.016</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;No</td><td align="left" colspan="1" rowspan="1">374 (92.12%)</td><td align="left" colspan="1" rowspan="1">164 (95.91%)</td><td align="left" colspan="1" rowspan="1">210 (89.36%)</td><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;Yes</td><td align="left" colspan="1" rowspan="1">32 (7.88%)</td><td align="left" colspan="1" rowspan="1">7 (4.09%)</td><td align="left" colspan="1" rowspan="1">25 (10.64%)</td><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">Other individual organ</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">0.604</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;No</td><td align="left" colspan="1" rowspan="1">337 (83.00%)</td><td align="left" colspan="1" rowspan="1">140 (81.87%)</td><td align="left" colspan="1" rowspan="1">197 (83.83%)</td><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;Yes</td><td align="left" colspan="1" rowspan="1">69 (17.00%)</td><td align="left" colspan="1" rowspan="1">31 (18.13%)</td><td align="left" colspan="1" rowspan="1">38 (16.17%)</td><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">Two or more organs or sites</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">0.082</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;No</td><td align="left" colspan="1" rowspan="1">357 (87.93%)</td><td align="left" colspan="1" rowspan="1">156 (91.23%)</td><td align="left" colspan="1" rowspan="1">201 (85.53%)</td><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;Yes</td><td align="left" colspan="1" rowspan="1">49 (12.07%)</td><td align="left" colspan="1" rowspan="1">15 (8.77%)</td><td align="left" colspan="1" rowspan="1">34 (14.47%)</td><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">Local recurrence</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">0.024</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;No</td><td align="left" colspan="1" rowspan="1">375 (92.36%)</td><td align="left" colspan="1" rowspan="1">152 (88.89%)</td><td align="left" colspan="1" rowspan="1">223 (94.89%)</td><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;Yes</td><td align="left" colspan="1" rowspan="1">31 (7.64%)</td><td align="left" colspan="1" rowspan="1">19 (11.11%)</td><td align="left" colspan="1" rowspan="1">12 (5.11%)</td><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">Sex, no. (%) of patients</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">0.738</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;Male</td><td align="left" colspan="1" rowspan="1">220 (54.19%)</td><td align="left" colspan="1" rowspan="1">91 (53.22%)</td><td align="left" colspan="1" rowspan="1">129 (54.89%)</td><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;Female</td><td align="left" colspan="1" rowspan="1">186 (45.81%)</td><td align="left" colspan="1" rowspan="1">80 (46.78%)</td><td align="left" colspan="1" rowspan="1">106 (45.11%)</td><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">Surgical approach</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">0.056</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;OR</td><td align="left" colspan="1" rowspan="1">291 (71.67%)</td><td align="left" colspan="1" rowspan="1">114 (66.67%)</td><td align="left" colspan="1" rowspan="1">177 (75.32%)</td><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;LR</td><td align="left" colspan="1" rowspan="1">115 (28.33%)</td><td align="left" colspan="1" rowspan="1">57 (33.33%)</td><td align="left" colspan="1" rowspan="1">58 (24.68%)</td><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">Primary site</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">0.102</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;Right colon</td><td align="left" colspan="1" rowspan="1">105 (25.86%)</td><td align="left" colspan="1" rowspan="1">36 (21.05%)</td><td align="left" colspan="1" rowspan="1">69 (29.36%)</td><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;Left colon</td><td align="left" colspan="1" rowspan="1">85 (20.94%)</td><td align="left" colspan="1" rowspan="1">42 (24.56%)</td><td align="left" colspan="1" rowspan="1">43 (18.30%)</td><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;Rectum</td><td align="left" colspan="1" rowspan="1">216 (53.20%)</td><td align="left" colspan="1" rowspan="1">93 (54.39%)</td><td align="left" colspan="1" rowspan="1">123 (52.34%)</td><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">Tumor differentiation, no. (%) of patients</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">0.340</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;Unknown</td><td align="left" colspan="1" rowspan="1">39 (9.61%)</td><td align="left" colspan="1" rowspan="1">17 (9.94%)</td><td align="left" colspan="1" rowspan="1">22 (9.36%)</td><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;Well</td><td align="left" colspan="1" rowspan="1">15 (3.69%)</td><td align="left" colspan="1" rowspan="1">6 (3.51%)</td><td align="left" colspan="1" rowspan="1">9 (3.83%)</td><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;Moderate</td><td align="left" colspan="1" rowspan="1">199 (49.01%)</td><td align="left" colspan="1" rowspan="1">92 (53.80%)</td><td align="left" colspan="1" rowspan="1">107 (45.53%)</td><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;Poor-undifferentiated</td><td align="left" colspan="1" rowspan="1">153 (37.68%)</td><td align="left" colspan="1" rowspan="1">56 (32.75%)</td><td align="left" colspan="1" rowspan="1">97 (41.28%)</td><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">Mucinous type</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">0.260</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;No</td><td align="left" colspan="1" rowspan="1">386 (95.07%)</td><td align="left" colspan="1" rowspan="1">165 (96.49%)</td><td align="left" colspan="1" rowspan="1">221 (94.04%)</td><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;Yes</td><td align="left" colspan="1" rowspan="1">20 (4.93%)</td><td align="left" colspan="1" rowspan="1">6 (3.51%)</td><td align="left" colspan="1" rowspan="1">14 (5.96%)</td><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">T stage, no. (%) of patients</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">0.068</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;T0</td><td align="left" colspan="1" rowspan="1">12 (2.96%)</td><td align="left" colspan="1" rowspan="1">8 (4.68%)</td><td align="left" colspan="1" rowspan="1">4 (1.70%)</td><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;T1</td><td align="left" colspan="1" rowspan="1">34 (8.37%)</td><td align="left" colspan="1" rowspan="1">18 (10.53%)</td><td align="left" colspan="1" rowspan="1">16 (6.81%)</td><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;T3</td><td align="left" colspan="1" rowspan="1">336 (82.76%)</td><td align="left" colspan="1" rowspan="1">132 (77.19%)</td><td align="left" colspan="1" rowspan="1">204 (86.81%)</td><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;T4</td><td align="left" colspan="1" rowspan="1">24 (5.91%)</td><td align="left" colspan="1" rowspan="1">13 (7.60%)</td><td align="left" colspan="1" rowspan="1">11 (4.68%)</td><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">N stage, no. (%) of patients</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">&#8201;&lt;&#8201;0.001</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;N0</td><td align="left" colspan="1" rowspan="1">158 (38.92%)</td><td align="left" colspan="1" rowspan="1">87 (50.88%)</td><td align="left" colspan="1" rowspan="1">71 (30.21%)</td><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;N1</td><td align="left" colspan="1" rowspan="1">149 (36.70%)</td><td align="left" colspan="1" rowspan="1">57 (33.33%)</td><td align="left" colspan="1" rowspan="1">92 (39.15%)</td><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;N2</td><td align="left" colspan="1" rowspan="1">99 (24.38%)</td><td align="left" colspan="1" rowspan="1">27 (15.79%)</td><td align="left" colspan="1" rowspan="1">72 (30.64%)</td><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">AJCC 8th ed. stage</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">&#8201;&lt;&#8201;0.001</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;I</td><td align="left" colspan="1" rowspan="1">39 (9.61%)</td><td align="left" colspan="1" rowspan="1">24 (14.04%)</td><td align="left" colspan="1" rowspan="1">15 (6.38%)</td><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;II</td><td align="left" colspan="1" rowspan="1">119 (29.31%)</td><td align="left" colspan="1" rowspan="1">63 (36.84%)</td><td align="left" colspan="1" rowspan="1">56 (23.83%)</td><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;III</td><td align="left" colspan="1" rowspan="1">248 (61.08%)</td><td align="left" colspan="1" rowspan="1">84 (49.12%)</td><td align="left" colspan="1" rowspan="1">164 (69.79%)</td><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">Lymph node yield, n (%)</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">0.267</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;&#8201;&lt;&#8201;12</td><td align="left" colspan="1" rowspan="1">98 (24.14%)</td><td align="left" colspan="1" rowspan="1">46 (26.90%)</td><td align="left" colspan="1" rowspan="1">52 (22.13%)</td><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;&#8201;&#8805;&#8201;12</td><td align="left" colspan="1" rowspan="1">308 (75.86%)</td><td align="left" colspan="1" rowspan="1">125 (73.10%)</td><td align="left" colspan="1" rowspan="1">183 (77.87%)</td><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">LVI</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">0.022</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;Unknown</td><td align="left" colspan="1" rowspan="1">54 (13.30%)</td><td align="left" colspan="1" rowspan="1">28 (16.37%)</td><td align="left" colspan="1" rowspan="1">26 (11.06%)</td><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;Yes</td><td align="left" colspan="1" rowspan="1">56 (13.79%)</td><td align="left" colspan="1" rowspan="1">15 (8.77%)</td><td align="left" colspan="1" rowspan="1">41 (17.45%)</td><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;No</td><td align="left" colspan="1" rowspan="1">296 (72.91%)</td><td align="left" colspan="1" rowspan="1">128 (74.85%)</td><td align="left" colspan="1" rowspan="1">168 (71.49%)</td><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">PNI</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">0.270</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;Unknown</td><td align="left" colspan="1" rowspan="1">81 (19.95%)</td><td align="left" colspan="1" rowspan="1">34 (19.88%)</td><td align="left" colspan="1" rowspan="1">47 (20.00%)</td><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;Yes</td><td align="left" colspan="1" rowspan="1">23 (5.67%)</td><td align="left" colspan="1" rowspan="1">6 (3.51%)</td><td align="left" colspan="1" rowspan="1">17 (7.23%)</td><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;No</td><td align="left" colspan="1" rowspan="1">302 (74.38%)</td><td align="left" colspan="1" rowspan="1">131 (76.61%)</td><td align="left" colspan="1" rowspan="1">171 (72.77%)</td><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">Tumor deposit, no. (%) of patients</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">0.191</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;No</td><td align="left" colspan="1" rowspan="1">340 (83.74%)</td><td align="left" colspan="1" rowspan="1">148 (86.55%)</td><td align="left" colspan="1" rowspan="1">192 (81.70%)</td><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;Yes</td><td align="left" colspan="1" rowspan="1">66 (16.26%)</td><td align="left" colspan="1" rowspan="1">23 (13.45%)</td><td align="left" colspan="1" rowspan="1">43 (18.30%)</td><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">Adjuvant chemotherapy, no. (%) of patients</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">0.635</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;No</td><td align="left" colspan="1" rowspan="1">109 (26.85%)</td><td align="left" colspan="1" rowspan="1">48 (28.07%)</td><td align="left" colspan="1" rowspan="1">61 (25.96%)</td><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;Yes</td><td align="left" colspan="1" rowspan="1">297 (73.15%)</td><td align="left" colspan="1" rowspan="1">123 (71.93%)</td><td align="left" colspan="1" rowspan="1">174 (74.04%)</td><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">Chemotherapy regimen</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">0.524</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;5-FU/capecitabine</td><td align="left" colspan="1" rowspan="1">25 (8.42%)</td><td align="left" colspan="1" rowspan="1">13 (10.57%)</td><td align="left" colspan="1" rowspan="1">12 (6.90%)</td><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;CAPOX/XELOX</td><td align="left" colspan="1" rowspan="1">90 (30.30%)</td><td align="left" colspan="1" rowspan="1">34 (27.64%)</td><td align="left" colspan="1" rowspan="1">56 (32.18%)</td><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;FOLFOX</td><td align="left" colspan="1" rowspan="1">164 (55.22%)</td><td align="left" colspan="1" rowspan="1">70 (56.91%)</td><td align="left" colspan="1" rowspan="1">94 (54.02%)</td><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;Other</td><td align="left" colspan="1" rowspan="1">18 (6.06%)</td><td align="left" colspan="1" rowspan="1">6 (4.88%)</td><td align="left" colspan="1" rowspan="1">12 (6.90%)</td><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">Chemotherapy cycle</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">0.748</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;&#8201;&lt;&#8201;6</td><td align="left" colspan="1" rowspan="1">153 (51.52%)</td><td align="left" colspan="1" rowspan="1">62 (50.41%)</td><td align="left" colspan="1" rowspan="1">91 (52.30%)</td><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;&#8201;&#8805;&#8201;6</td><td align="left" colspan="1" rowspan="1">144 (48.48%)</td><td align="left" colspan="1" rowspan="1">61 (49.59%)</td><td align="left" colspan="1" rowspan="1">83 (47.70%)</td><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">Adjuvant radiotherapy</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">0.197</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;No</td><td align="left" colspan="1" rowspan="1">385 (94.83%)</td><td align="left" colspan="1" rowspan="1">165 (96.49%)</td><td align="left" colspan="1" rowspan="1">220 (93.62%)</td><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;Yes</td><td align="left" colspan="1" rowspan="1">21 (5.17%)</td><td align="left" colspan="1" rowspan="1">6 (3.51%)</td><td align="left" colspan="1" rowspan="1">15 (6.38%)</td><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">Palliative chemotherapy</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">0.581</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;No</td><td align="left" colspan="1" rowspan="1">32 (7.88%)</td><td align="left" colspan="1" rowspan="1">12 (7.02%)</td><td align="left" colspan="1" rowspan="1">20 (8.51%)</td><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;Yes</td><td align="left" colspan="1" rowspan="1">374 (92.12%)</td><td align="left" colspan="1" rowspan="1">159 (92.98%)</td><td align="left" colspan="1" rowspan="1">215 (91.49%)</td><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="5" rowspan="1">Preoperative CEA, ng/mL</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;Mean (SD)</td><td align="left" colspan="1" rowspan="1">31.22 (254.29)</td><td align="left" colspan="1" rowspan="1">13.14 (23.55)</td><td align="left" colspan="1" rowspan="1">44.34 (333.10)</td><td align="left" rowspan="2" colspan="1">0.225</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;Median (IQR)</td><td align="left" colspan="1" rowspan="1">5.33 (0.20&#8211;4688.00)</td><td align="left" colspan="1" rowspan="1">4.13 (0.49&#8211;150.50)</td><td align="left" colspan="1" rowspan="1">5.87 (0.20&#8211;4688.00)</td></tr><tr><td align="left" colspan="5" rowspan="1">Preoperative CA19-9, ng/ml Mean</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;(SD)</td><td align="left" colspan="1" rowspan="1">37.82 (90.08)</td><td align="left" colspan="1" rowspan="1">25.42 (36.39)</td><td align="left" colspan="1" rowspan="1">46.80 (113.46)</td><td align="left" rowspan="2" colspan="1">0.020</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;Median (IQR)</td><td align="left" colspan="1" rowspan="1">15.53 (0.59&#8211;1405.00)</td><td align="left" colspan="1" rowspan="1">14.80 (0.60&#8211;253.10)</td><td align="left" colspan="1" rowspan="1">16.78 (0.59&#8211;1405.00)</td></tr><tr><td align="left" colspan="5" rowspan="1">Postoperative CEA, ng/mL Mean</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;(SD)</td><td align="left" colspan="1" rowspan="1">34.36 (233.80)</td><td align="left" colspan="1" rowspan="1">5.55 (16.92)</td><td align="left" colspan="1" rowspan="1">55.41 (305.78)</td><td align="left" rowspan="2" colspan="1">0.042</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;Median (IQR)</td><td align="left" colspan="1" rowspan="1">2.38 (0.20&#8211;2965.00)</td><td align="left" colspan="1" rowspan="1">2.00 (0.20&#8211;174.60)</td><td align="left" colspan="1" rowspan="1">2.72 (0.20&#8211;2965.00)</td></tr></tbody></table><table-wrap-foot><p>1 Data are presented as median (IQR), mean (SD), or n (%)</p><p>2 <italic toggle="yes">Abbreviations</italic>: <italic toggle="yes">PRS</italic> post-recurrence survival, <italic toggle="yes">RFS</italic> recurrence-free survival, <italic toggle="yes">BMI</italic> Body Mass Index, <italic toggle="yes">CEA</italic> carcinoembryonic antigen, <italic toggle="yes">CA 19&#8211;9</italic> carcinoma antigen 19&#8211;9, <italic toggle="yes">LR</italic> laparoscopic resection, <italic toggle="yes">LVI</italic> lymphovascular invasion, <italic toggle="yes">OR</italic> open resection, <italic toggle="yes">PNI</italic> perineural invasion</p><p>3 <italic toggle="yes">P</italic> value, using Wilcoxon Mann&#8211;Whitney test, chi-square test, or exact Fisher test depending on whether the variable is continuous or categorical</p></table-wrap-foot></table-wrap></p><p id="Par22">The 3-year PRS rate of 252 patients with early relapse was 44.59% (95% CI, 38.85%-51.19%), whereas the 3-year PRS rate of 154 patients with late recurrence was 53.28% (95% CI, 46.20%-61.45%) (HR, 0.78; 95% CI, 0.59&#8211;1.02; <italic toggle="yes">P</italic>&#8201;=&#8201;0.0717) (Table <xref rid="Tab2" ref-type="table">2</xref> and Fig.&#160;<xref rid="Fig2" ref-type="fig">2</xref>A). The 3-year PRS of patients with local recurrence was 66.83% (95% CI, 53.04%-84.22%), and the 3-year PRS of patients with distant metastasis was 49.41% (95% CI, 44.16%-55.27%), which were significantly greater than the 3-year PRS in patients with synchronous recurrence and metastasis (30.32%; 95% CI, 21.10%-43.56%) (Table <xref rid="Tab2" ref-type="table">2</xref> and Fig.&#160;<xref rid="Fig2" ref-type="fig">2</xref>B). The 3-year PRS of patients with simple liver metastases was 54.04% (95% CI, 45.46%-64.24%), and the 3-year PRS of patients with simple pulmonary metastases was 50.05% (95% CI, 42.50%-58.95%). No significant difference was observed in patients with relapse. The 3-year PRS of patients with peritoneal metastases was 25.43% (95% CI, 14.76%-43.82%), and the 3-year PRS of patients with metastases to two or more organs was 34.84% (95% CI, 24.16%-50.24%) (Table <xref rid="Tab2" ref-type="table">2</xref> and Fig.&#160;<xref rid="Fig2" ref-type="fig">2</xref>C).<table-wrap id="Tab2" position="float" orientation="portrait"><label>Table 2</label><caption><p>Univariate and multivariate analyses of 3-year post-recurrence survival</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" colspan="1" rowspan="1">Variables</th><th align="left" colspan="1" rowspan="1">3-year PRS (95% CI)</th><th align="left" colspan="1" rowspan="1">Univariate</th><th align="left" colspan="1" rowspan="1"/><th align="left" colspan="1" rowspan="1">Multivariate</th><th align="left" colspan="1" rowspan="1"/></tr><tr><th align="left" colspan="1" rowspan="1">Recurrence group</th><th align="left" colspan="1" rowspan="1"/><th align="left" colspan="1" rowspan="1">HR (95% CI)</th><th align="left" colspan="1" rowspan="1"><italic toggle="yes">P</italic>-value</th><th align="left" colspan="1" rowspan="1">HR (95% CI)</th><th align="left" colspan="1" rowspan="1"><italic toggle="yes">P</italic>-value</th></tr></thead><tbody><tr><td align="left" colspan="1" rowspan="1">Local recurrence</td><td align="left" colspan="1" rowspan="1">66.83 (53.04, 84.22)</td><td align="left" colspan="1" rowspan="1">1.0 (reference)</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">1.0 (reference)</td><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">Distant metastasis</td><td align="left" colspan="1" rowspan="1">49.41 (44.16, 55.27)</td><td align="left" colspan="1" rowspan="1">1.75 (0.97, 3.15)</td><td align="left" colspan="1" rowspan="1">0.0618</td><td align="left" colspan="1" rowspan="1">1.19 (0.60, 2.38)</td><td align="left" colspan="1" rowspan="1">0.6185</td></tr><tr><td align="left" colspan="1" rowspan="1">Simultaneous recurrence</td><td align="left" colspan="1" rowspan="1">30.32 (21.10, 43.56)</td><td align="left" colspan="1" rowspan="1">2.96 (1.56, 5.62)</td><td align="left" colspan="1" rowspan="1">0.0009</td><td align="left" colspan="1" rowspan="1">2.17 (1.01, 4.64)</td><td align="left" colspan="1" rowspan="1"><bold>0.0465</bold></td></tr><tr><td align="left" colspan="6" rowspan="1">Recurrence time</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;Early recurrence</td><td align="left" colspan="1" rowspan="1">44.59 (38.85, 51.19)</td><td align="left" colspan="1" rowspan="1">1.0 (reference)</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;Late recurrence</td><td align="left" colspan="1" rowspan="1">53.28 (46.20, 61.45)</td><td align="left" colspan="1" rowspan="1">0.78 (0.59, 1.02)</td><td align="left" colspan="1" rowspan="1">0.0717</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="6" rowspan="1">Recurrence site</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;Liver</td><td align="left" colspan="1" rowspan="1">54.04 (45.46, 64.24)</td><td align="left" colspan="1" rowspan="1">1.0 (reference)</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;Lung</td><td align="left" colspan="1" rowspan="1">50.05 (42.50, 58.95)</td><td align="left" colspan="1" rowspan="1">1.12 (0.79, 1.61)</td><td align="left" colspan="1" rowspan="1">0.5172</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;Peritoneum</td><td align="left" colspan="1" rowspan="1">25.43 (14.76, 43.82)</td><td align="left" colspan="1" rowspan="1">2.23 (1.38, 3.60)</td><td align="left" colspan="1" rowspan="1">0.0011</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;Other individual organ</td><td align="left" colspan="1" rowspan="1">46.26 (36.03, 59.40)</td><td align="left" colspan="1" rowspan="1">1.25 (0.82, 1.91)</td><td align="left" colspan="1" rowspan="1">0.2943</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;Two or more organs or sites</td><td align="left" colspan="1" rowspan="1">34.84 (24.16, 50.24)</td><td align="left" colspan="1" rowspan="1">1.71 (1.10, 2.66)</td><td align="left" colspan="1" rowspan="1">0.0163</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;Local recurrence</td><td align="left" colspan="1" rowspan="1">66.99 (53.23, 84.32)</td><td align="left" colspan="1" rowspan="1">0.65 (0.35, 1.22)</td><td align="left" colspan="1" rowspan="1">0.1829</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">Liver</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;No</td><td align="left" colspan="1" rowspan="1">46.00 (40.68, 52.01)</td><td align="left" colspan="1" rowspan="1">1.0 (reference)</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;Yes</td><td align="left" colspan="1" rowspan="1">54.04 (45.46, 64.24)</td><td align="left" colspan="1" rowspan="1">0.80 (0.58, 1.09)</td><td align="left" colspan="1" rowspan="1">0.1526</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="6" rowspan="1">Lung</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;No</td><td align="left" colspan="1" rowspan="1">47.03 (41.47, 53.34)</td><td align="left" colspan="1" rowspan="1">1.0 (reference)</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;Yes</td><td align="left" colspan="1" rowspan="1">50.05 (42.50, 58.95)</td><td align="left" colspan="1" rowspan="1">0.92 (0.70, 1.22)</td><td align="left" colspan="1" rowspan="1">0.5704</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="6" rowspan="1">Peritoneum</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;No</td><td align="left" colspan="1" rowspan="1">49.89 (44.96, 55.36)</td><td align="left" colspan="1" rowspan="1">1.0 (reference)</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">1.0 (reference)</td><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;Yes</td><td align="left" colspan="1" rowspan="1">25.43 (14.76, 43.82)</td><td align="left" colspan="1" rowspan="1">1.97 (1.30, 2.98)</td><td align="left" colspan="1" rowspan="1">0.0015</td><td align="left" colspan="1" rowspan="1">1.75 (1.10, 2.79)</td><td align="left" colspan="1" rowspan="1"><bold>0.0189</bold></td></tr><tr><td align="left" colspan="6" rowspan="1">Other individual organ</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;No</td><td align="left" colspan="1" rowspan="1">48.29 (43.20, 53.99)</td><td align="left" colspan="1" rowspan="1">1.0 (reference)</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;Yes</td><td align="left" colspan="1" rowspan="1">46.26 (36.03, 59.40)</td><td align="left" colspan="1" rowspan="1">1.06 (0.75, 1.50)</td><td align="left" colspan="1" rowspan="1">0.7323</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="6" rowspan="1">Two or more organs or sites</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;No</td><td align="left" colspan="1" rowspan="1">49.68 (44.67, 55.26)</td><td align="left" colspan="1" rowspan="1">1.0 (reference)</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">1.0 (reference)</td><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;Yes</td><td align="left" colspan="1" rowspan="1">34.84 (24.16, 50.24)</td><td align="left" colspan="1" rowspan="1">1.51 (1.04, 2.18)</td><td align="left" colspan="1" rowspan="1">0.0296</td><td align="left" colspan="1" rowspan="1">1.59 (1.05, 2.43)</td><td align="left" colspan="1" rowspan="1"><bold>0.0304</bold></td></tr><tr><td align="left" colspan="6" rowspan="1">Local recurrence</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;No</td><td align="left" colspan="1" rowspan="1">46.47 (41.59, 51.93)</td><td align="left" colspan="1" rowspan="1">1.0 (reference)</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">1.0 (reference)</td><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;Yes</td><td align="left" colspan="1" rowspan="1">66.99 (53.23, 84.32)</td><td align="left" colspan="1" rowspan="1">0.53 (0.29, 0.94)</td><td align="left" colspan="1" rowspan="1">0.0310</td><td align="left" colspan="1" rowspan="1">0.48 (0.22, 1.03)</td><td align="left" colspan="1" rowspan="1">0.0582</td></tr><tr><td align="left" colspan="6" rowspan="1">Sex</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;Male</td><td align="left" colspan="1" rowspan="1">46.60 (40.50, 53.62)</td><td align="left" colspan="1" rowspan="1">1.0 (reference)</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;Female</td><td align="left" colspan="1" rowspan="1">49.51 (43.00, 57.00)</td><td align="left" colspan="1" rowspan="1">0.92 (0.71, 1.19)</td><td align="left" colspan="1" rowspan="1">0.5295</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="6" rowspan="1">Surgical approach</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;OR</td><td align="left" colspan="1" rowspan="1">46.87 (41.46, 52.98)</td><td align="left" colspan="1" rowspan="1">1.0 (reference)</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;LR</td><td align="left" colspan="1" rowspan="1">50.83 (42.56, 60.72)</td><td align="left" colspan="1" rowspan="1">0.89 (0.66, 1.20)</td><td align="left" colspan="1" rowspan="1">0.4556</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="6" rowspan="1">Primary site</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;Right colon</td><td align="left" colspan="1" rowspan="1">41.69 (33.70, 51.57)</td><td align="left" colspan="1" rowspan="1">1.0 (reference)</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">1.0 (reference)</td><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;Left colon</td><td align="left" colspan="1" rowspan="1">55.91 (46.70, 66.95)</td><td align="left" colspan="1" rowspan="1">0.66 (0.45, 0.98)</td><td align="left" colspan="1" rowspan="1">0.0370</td><td align="left" colspan="1" rowspan="1">0.67 (0.44, 1.01)</td><td align="left" colspan="1" rowspan="1">0.0538</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;Rectum</td><td align="left" colspan="1" rowspan="1">48.02 (41.85, 55.10)</td><td align="left" colspan="1" rowspan="1">0.84 (0.62, 1.13)</td><td align="left" colspan="1" rowspan="1">0.2419</td><td align="left" colspan="1" rowspan="1">0.87 (0.62, 1.24)</td><td align="left" colspan="1" rowspan="1">0.4475</td></tr><tr><td align="left" colspan="6" rowspan="1">Tumor differentiation</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;Well</td><td align="left" colspan="1" rowspan="1">56.79 (38.27, 84.26)</td><td align="left" colspan="1" rowspan="1">1.0 (reference)</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;Moderate</td><td align="left" colspan="1" rowspan="1">52.61 (46.24, 59.87)</td><td align="left" colspan="1" rowspan="1">1.13 (0.55, 2.33)</td><td align="left" colspan="1" rowspan="1">0.7300</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;Poor-undifferentiated</td><td align="left" colspan="1" rowspan="1">41.62 (34.63, 50.03)</td><td align="left" colspan="1" rowspan="1">1.55 (0.75, 3.19)</td><td align="left" colspan="1" rowspan="1">0.2346</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="6" rowspan="1">Mucinous type</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;No</td><td align="left" colspan="1" rowspan="1">48.48 (43.62, 53.89)</td><td align="left" colspan="1" rowspan="1">1.0 (reference)</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;Yes</td><td align="left" colspan="1" rowspan="1">38.25 (23.05, 63.47)</td><td align="left" colspan="1" rowspan="1">1.33 (0.77, 2.28)</td><td align="left" colspan="1" rowspan="1">0.3054</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="6" rowspan="1">T stag</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;T0</td><td align="left" colspan="1" rowspan="1">70.85 (50.49, 99.41)</td><td align="left" colspan="1" rowspan="1">1.0 (reference)</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;T1</td><td align="left" colspan="1" rowspan="1">65.86 (53.18, 81.58)</td><td align="left" colspan="1" rowspan="1">1.21 (0.40, 3.66)</td><td align="left" colspan="1" rowspan="1">0.7313</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;T3</td><td align="left" colspan="1" rowspan="1">44.65 (39.55, 50.41)</td><td align="left" colspan="1" rowspan="1">2.34 (0.87, 6.30)</td><td align="left" colspan="1" rowspan="1">0.0921</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;T4</td><td align="left" colspan="1" rowspan="1">55.71 (39.35, 78.86)</td><td align="left" colspan="1" rowspan="1">1.70 (0.54, 5.34)</td><td align="left" colspan="1" rowspan="1">0.3646</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="6" rowspan="1">N stag</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;N0</td><td align="left" colspan="1" rowspan="1">63.07 (56.29, 70.66)</td><td align="left" colspan="1" rowspan="1">1.0 (reference)</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">1.0 (reference)</td><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;N1</td><td align="left" colspan="1" rowspan="1">44.06 (36.95, 52.53)</td><td align="left" colspan="1" rowspan="1">1.78 (1.30, 2.43)</td><td align="left" colspan="1" rowspan="1">0.0003</td><td align="left" colspan="1" rowspan="1">1.49 (1.04, 2.15)</td><td align="left" colspan="1" rowspan="1"><bold>0.0315</bold></td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;N2</td><td align="left" colspan="1" rowspan="1">26.55 (21.13, 38.57)</td><td align="left" colspan="1" rowspan="1">2.72 (1.95, 3.79)</td><td align="left" colspan="1" rowspan="1">&#8201;&lt;&#8201;0.0001</td><td align="left" colspan="1" rowspan="1">2.07 (1.41, 3.03)</td><td align="left" colspan="1" rowspan="1"><bold>0.0002</bold></td></tr><tr><td align="left" colspan="6" rowspan="1">AJCC 8th ed. stage</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;I</td><td align="left" colspan="1" rowspan="1">62.01 (52.16, 67.18)</td><td align="left" colspan="1" rowspan="1">1.0 (reference)</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;II</td><td align="left" colspan="1" rowspan="1">48.63 (38.74, 54.83)</td><td align="left" colspan="1" rowspan="1">1.52 (0.85, 2.73)</td><td align="left" colspan="1" rowspan="1">0.1617</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;III</td><td align="left" colspan="1" rowspan="1">23.57 (20.94, 34.72)</td><td align="left" colspan="1" rowspan="1">2.88 (1.66, 4.97)</td><td align="left" colspan="1" rowspan="1">0.0002</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="6" rowspan="1">Lymph node yield</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;&#8201;&lt;&#8201;12</td><td align="left" colspan="1" rowspan="1">67.23 (59.97, 70.52)</td><td align="left" colspan="1" rowspan="1">1.0 (reference)</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;&#8201;&#8805;&#8201;12</td><td align="left" colspan="1" rowspan="1">59.82 (54.82, 68.51)</td><td align="left" colspan="1" rowspan="1">1.12 (0.82, 1.53)</td><td align="left" colspan="1" rowspan="1">0.4740</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="6" rowspan="1">LVI</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;No</td><td align="left" colspan="1" rowspan="1">52.37 (49.98, 55.01)</td><td align="left" colspan="1" rowspan="1">1.0 (reference)</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">1.0 (reference)</td><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;Yes</td><td align="left" colspan="1" rowspan="1">40.32 (38.92, 45.08)</td><td align="left" colspan="1" rowspan="1">2.01 (1.23, 3.29)</td><td align="left" colspan="1" rowspan="1">0.0054</td><td align="left" colspan="1" rowspan="1">1.46 (0.86, 2.50)</td><td align="left" colspan="1" rowspan="1">0.1628</td></tr><tr><td align="left" colspan="6" rowspan="1">PNI</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;No</td><td align="left" colspan="1" rowspan="1">66.69 (60.83, 72.90)</td><td align="left" colspan="1" rowspan="1">1.0 (reference)</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;Yes</td><td align="left" colspan="1" rowspan="1">62.75 (59.38, 68.47)</td><td align="left" colspan="1" rowspan="1">1.57 (0.90, 2.73)</td><td align="left" colspan="1" rowspan="1">0.1121</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="6" rowspan="1">TD</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;No</td><td align="left" colspan="1" rowspan="1">59.21 (55.34, 62.07)</td><td align="left" colspan="1" rowspan="1">1.0 (reference)</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">1.0 (reference)</td><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;Yes</td><td align="left" colspan="1" rowspan="1">49.10 (45.12, 52.55)</td><td align="left" colspan="1" rowspan="1">1.46 (1.05, 2.04)</td><td align="left" colspan="1" rowspan="1">0.0248</td><td align="left" colspan="1" rowspan="1">1.10 (0.74, 1.65)</td><td align="left" colspan="1" rowspan="1">0.6262</td></tr><tr><td align="left" colspan="6" rowspan="1">Adjuvant chemotherapy</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;No</td><td align="left" colspan="1" rowspan="1">63.17 (57.82, 65.10)</td><td align="left" colspan="1" rowspan="1">1.0 (reference)</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;Yes</td><td align="left" colspan="1" rowspan="1">55.86 (50.16, 60.04)</td><td align="left" colspan="1" rowspan="1">0.99 (0.74, 1.32)</td><td align="left" colspan="1" rowspan="1">0.9380</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="6" rowspan="1">Chemotherapy regimen</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;5-FU/capecitabine</td><td align="left" colspan="1" rowspan="1">66.81 (61.90, 67.21)</td><td align="left" colspan="1" rowspan="1">1.0 (reference)</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;CAPOX/XELOX</td><td align="left" colspan="1" rowspan="1">60.52 (58.42, 62.00)</td><td align="left" colspan="1" rowspan="1">1.62 (0.87, 3.03)</td><td align="left" colspan="1" rowspan="1">0.1284</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;FOLFOX</td><td align="left" colspan="1" rowspan="1">53.26 (50.86, 65.33)</td><td align="left" colspan="1" rowspan="1">1.49 (0.82, 2.72)</td><td align="left" colspan="1" rowspan="1">0.1931</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;Other</td><td align="left" colspan="1" rowspan="1">57.82 (51.78, 64.93)</td><td align="left" colspan="1" rowspan="1">1.80 (0.81, 4.01)</td><td align="left" colspan="1" rowspan="1">0.1510</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="6" rowspan="1">Chemotherapy cycle</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;&#8201;&lt;&#8201;6</td><td align="left" colspan="1" rowspan="1">51.42 (48.26, 58.95)</td><td align="left" colspan="1" rowspan="1">1.0 (reference)</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;&#8201;&#8805;&#8201;6</td><td align="left" colspan="1" rowspan="1">59.71 (54.01, 63.29)</td><td align="left" colspan="1" rowspan="1">0.86 (0.64, 1.16)</td><td align="left" colspan="1" rowspan="1">0.3113</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="6" rowspan="1">Adjuvant radiotherapy</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;No</td><td align="left" colspan="1" rowspan="1">59.28 (51.90, 62.77)</td><td align="left" colspan="1" rowspan="1">1.0 (reference)</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;Yes</td><td align="left" colspan="1" rowspan="1">58.01 (51.00, 58.52)</td><td align="left" colspan="1" rowspan="1">0.68 (0.43, 1.07)</td><td align="left" colspan="1" rowspan="1">0.0950</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="6" rowspan="1">Palliative chemotherapy</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;No</td><td align="left" colspan="1" rowspan="1">57.02 (49.72, 60.73)</td><td align="left" colspan="1" rowspan="1">1.0 (reference)</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;Yes</td><td align="left" colspan="1" rowspan="1">55.88 (50.14, 58.92)</td><td align="left" colspan="1" rowspan="1">1.10 (0.84, 1.44)</td><td align="left" colspan="1" rowspan="1">0.5048</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="6" rowspan="1">Age group</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;&#8201;&lt;&#8201;65</td><td align="left" colspan="1" rowspan="1">60.27 (53.93, 64.07)</td><td align="left" colspan="1" rowspan="1">1.0 (reference)</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;&#8201;&#8805;&#8201;65</td><td align="left" colspan="1" rowspan="1">57.82 (53.87, 62.05)</td><td align="left" colspan="1" rowspan="1">0.95 (0.72, 1.26)</td><td align="left" colspan="1" rowspan="1">0.7132</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="6" rowspan="1">BM group</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;&#8201;&lt;&#8201;24</td><td align="left" colspan="1" rowspan="1">56.87 (48.97, 57.65)</td><td align="left" colspan="1" rowspan="1">1.0 (reference)</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">1.0 (reference)</td><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;&#8201;&#8805;&#8201;24</td><td align="left" colspan="1" rowspan="1">40.67 (31.98, 44.06)</td><td align="left" colspan="1" rowspan="1">1.46 (1.12, 1.89)</td><td align="left" colspan="1" rowspan="1">0.0046</td><td align="left" colspan="1" rowspan="1">1.12 (0.81, 1.54)</td><td align="left" colspan="1" rowspan="1">0.4850</td></tr><tr><td align="left" colspan="6" rowspan="1">Preoperative CEA group</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;&#8201;&lt;&#8201;5</td><td align="left" colspan="1" rowspan="1">43.82 (39.92, 52.06)</td><td align="left" colspan="1" rowspan="1">1.0 (reference)</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">1.0 (reference)</td><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;&#8201;&#8805;&#8201;5</td><td align="left" colspan="1" rowspan="1">46.92 (41.77, 49.27)</td><td align="left" colspan="1" rowspan="1">1.44 (1.06, 1.95)</td><td align="left" colspan="1" rowspan="1">0.0183</td><td align="left" colspan="1" rowspan="1">1.29 (0.92, 1.80)</td><td align="left" colspan="1" rowspan="1">0.1336</td></tr><tr><td align="left" colspan="6" rowspan="1">Preoperative CA19-9 group</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;&#8201;&lt;&#8201;37</td><td align="left" colspan="1" rowspan="1">49.82 (45.34, 54.37)</td><td align="left" colspan="1" rowspan="1">1.0 (reference)</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">1.0 (reference)</td><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;&#8201;&#8805;&#8201;37</td><td align="left" colspan="1" rowspan="1">30.62 (28.54, 42.45)</td><td align="left" colspan="1" rowspan="1">1.80 (1.35, 2.40)</td><td align="left" colspan="1" rowspan="1">&#8201;&lt;&#8201;0.0001</td><td align="left" colspan="1" rowspan="1">1.31 (0.93, 1.85)</td><td align="left" colspan="1" rowspan="1">0.1170</td></tr></tbody></table><table-wrap-foot><p>1 <italic toggle="yes">Abbreviations</italic>: <italic toggle="yes">APR</italic> abdominoperineal resection, <italic toggle="yes">BMI</italic> Body Mass Index, <italic toggle="yes">CEA</italic> carcinoembryonic antigen, <italic toggle="yes">CA 19&#8211;9</italic> carcinoma antigen 19&#8211;9, <italic toggle="yes">LAR</italic> low anterior resection, <italic toggle="yes">LR</italic> laparoscopic resection, <italic toggle="yes">OR</italic> open resection</p></table-wrap-foot></table-wrap><fig id="Fig2" position="float" orientation="portrait"><label>Fig. 2</label><caption><p>There was no significant difference in the PRS between patients with early recurrence and late recurrence (<bold>A</bold>). The PRS of synchronous recurrence was significantly lower than that of distant metastasis. Patients with local recurrence had the longest survival (<bold>B</bold>). The PRS of patients with metastasis to the peritoneum or two or more organs or sites was significantly lower than that of patients with recurrence in other sites (<bold>C</bold>). PRS: Post-recurrence survival rate</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="MO2" position="float" orientation="portrait" xlink:href="12957_2023_3015_Fig2_HTML.jpg"/></fig></p><p id="Par23">Univariate and multivariate analyses of the factors associated with PRS are shown in Table <xref rid="Tab2" ref-type="table">2</xref>. Univariate analysis showed that peritoneal metastasis, metastasis to two or more organs or sites, distant metastasis, right colon and rectal cancer, later pathological N stage, vascular invasion, tumor deposition, preoperative CEA, CA199 elevation, and postoperative CEA elevation were associated with a shorter PRS. Metastasis to the peritoneum (hazard ratio [HR], 1.75; 95% CI, 1.10&#8211;2.79; <italic toggle="yes">P</italic>&#8201;=&#8201;0.0189) and two or more organs or sites (HR, 1.59; 95% CI, 1.05&#8211;2.43; <italic toggle="yes">P</italic>&#8201;=&#8201;0.0189) in multivariate analysis (0.0304) along with a later pathological N stage was an independent poor prognostic factor for PRS (Table <xref rid="Tab2" ref-type="table">2</xref>).</p><p id="Par24">The 3-year PRS rate was 25.43% (95% CI, 14.76%-43.82%) in patients with peritoneal recurrence, in contrast to 49.89% (95% CI, 44.96%-55.36%) in patients without peritoneal recurrence (HR, 1.97; 95% CI, 1.30&#8211;2.98; <italic toggle="yes">P</italic>&#8201;=&#8201;0.0015) (Table <xref rid="Tab2" ref-type="table">2</xref> and Fig.&#160;<xref rid="Fig3" ref-type="fig">3</xref>C). The 3-year PRS rate was 34.84% (95% CI, 24.16%-50.24%) in patients with recurrence in two or more organ sites, whereas in patients with recurrence in other individual organs (including liver alone, lung alone, peritoneum, local metastasis, or metastasis in other sites), the 3-year PRS rate was 49.68% (95% CI, 44.67%-55.26%) (HR, 1.51; 95% CI, 1.04&#8211;2.18; <italic toggle="yes">P</italic>&#8201;=&#8201;0.0296) (Table <xref rid="Tab2" ref-type="table">2</xref> and Fig.&#160;<xref rid="Fig3" ref-type="fig">3</xref>E). The 3-year PRS rate was 66.99% (95% CI, 53.23%-84.32%) in patients with local recurrence, compared with 46.47% (95% CI, 41.59%-51.93%) in patients without local recurrence (HR, 0.51; 95% CI, 0.29&#8211;0.94; <italic toggle="yes">P</italic>&#8201;=&#8201;0.0310) (Table <xref rid="Tab2" ref-type="table">2</xref> and Fig.&#160;<xref rid="Fig3" ref-type="fig">3</xref>F). No significant difference was observed in the 3-year PRS between patients with and without liver metastases alone, lung metastases alone, and metastases to other individual organs (<italic toggle="yes">P</italic>&#8201;&gt;&#8201;0.05) (Fig. <xref rid="Fig3" ref-type="fig">3</xref>A, B, D).<fig id="Fig3" position="float" orientation="portrait"><label>Fig. 3</label><caption><p>Patients with metastasis to the peritoneum or two or more organs or sites and local recurrence had worse PRS than patients without metastasis to the peritoneum or two or more organs or sites and local recurrence (<bold>C</bold>, <bold>E</bold>, and <bold>F</bold>). No significant differences were observed in the PRS of patients with or without recurrence at other sites (<bold>A</bold>, <bold>B</bold>, and <bold>D</bold>). PRS: Post-recurrence survival</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="MO3" position="float" orientation="portrait" xlink:href="12957_2023_3015_Fig3_HTML.jpg"/></fig></p></sec><sec id="Sec9"><title>Discussion</title><p id="Par25">The key finding of this study is that the prognosis of patients with local recurrence is the same as that of patients with liver or lung metastases alone. Patients with peritoneal metastases and metastases to two or more organ sites had the worst prognosis, and these were independent poor prognostic factors for PRS. Sawayama et al. demonstrated that liver metastases are associated with early recurrence in patients with stage I-III CRC [<xref ref-type="bibr" rid="CR10">10</xref>]. Patients with hepatic recurrence with dissemination had a shorter PRS after recurrence compared with patients with recurrence in other organs. Patients with recurrence in the lungs had better prognosis than patients with recurrence in other organs. The number of metastatic organs and invasive treatment was correlated with patient prognosis. Future studies on the number of initial recurrences and treatment strategies for organs may help improve the prognosis of patients with colorectal cancer post recurrence.</p><p id="Par26">In this study, we analyzed the data of patients who exhibited relapse within 2&#160;years and those who exhibited relapse after 2&#160;years and found no significant difference in the prognosis between the two groups. Possibly, 2&#160;years is not the optimal cut-off value for assessing RFS. Evidence from studies has confirmed that colorectal cancer recurrence within 16&#160;months of initial treatment should be marked as "early stage." A primary tumor stage of pT3,4/ypT3,4 and positive lymph node status pN&#8201;+&#8201;/ypN&#8201;+&#8201;predict early recurrence [<xref ref-type="bibr" rid="CR11">11</xref>]. In other studies, patients with early recurrence of less than 13&#160;months showed significantly shortened post-recurrence overall survival. Higher preoperative CA19-9 levels, venous invasion, and the absence of adjuvant chemotherapy were associated with early recurrence [<xref ref-type="bibr" rid="CR12">12</xref>].</p><p id="Par27">This study also showed that the incidence of pure lung metastases was higher than that of pure liver metastases. The potential reason is that we included 216 (53.20%) patients with rectal cancer. Patients with primary rectal cancer have been shown to be more likely to develop lung metastases than patients with colon cancer [<xref ref-type="bibr" rid="CR13">13</xref>]. Clinical studies on colorectal cancer have shown differences in the metastatic patterns between mucinous adenocarcinoma, signet ring cell carcinoma, and the more common adenocarcinoma. Adenocarcinoma primarily metastasizes to the liver, whereas peritoneal metastasis is more common in mucinous adenocarcinoma and signet ring cell carcinoma [<xref ref-type="bibr" rid="CR14">14</xref>]. Clinicopathological and prognostic differences between signet-ring cell carcinoma (SRCC) and adenocarcinoma (ADC) in colorectal cancer. SRCC is more likely than ADC to have a lymphatic and perineural invasion, resulting in significantly poorer survival outcomes. Improving the therapeutic effect of peritoneal metastasis may be the key to the treatment of SRCC[<xref ref-type="bibr" rid="CR15">15</xref>].</p><p id="Par28">When organs other than the liver were analyzed for metastases, the location was found to affect the metastatic patterns. Rectal cancers are more likely to metastasize to the chest, nervous system, and bones, whereas colon cancers are more likely to metastasize to the peritoneum [<xref ref-type="bibr" rid="CR16">16</xref>]. The overall metastasis rate (including that of liver or lung metastasis) of right hemicolectomy has been shown to be lower. Meanwhile, left hemicolectomy has a higher rate of liver metastases. Sigmoidectomy has higher rates of liver, pulmonary, and brain metastases [<xref ref-type="bibr" rid="CR17">17</xref>]. Patients with liver metastases from right-sided colon cancer have a worse prognosis than patients with liver metastases from left-sided colon cancer and are less likely to require re-excision [<xref ref-type="bibr" rid="CR18">18</xref>]. The overall survival of patients with peritoneal recurrence was worse than that of patients with recurrence at other sites. In a study of 2077 patients with stage II or III colon cancer, female patients, stage T4, mucinous adenocarcinoma or signet ring cell carcinoma, and right colon cancer were associated with a significantly greater risk of postoperative peritoneal recurrence [<xref ref-type="bibr" rid="CR19">19</xref>].</p><p id="Par29">Some patients with post-recurrence metastatic colorectal cancer can be cured with surgery. Longer survival can be achieved by palliative chemotherapy, interventional therapy, radiofrequency treatment, and intraperitoneal hyperthermic perfusion chemotherapy. A careful follow-up and timely intervention of patients with colorectal cancer with progressive disease are essential components of the management strategy recommended by multidisciplinary treatment teams. Surgery should be combined with systemic chemotherapy in the treatment of colorectal cancer liver metastases [<xref ref-type="bibr" rid="CR20">20</xref>]. Radiofrequency ablation of colorectal lung metastases can help achieve good long-term survival with a low incidence of serious adverse events [<xref ref-type="bibr" rid="CR21">21</xref>]. Hyperthermic intraperitoneal chemotherapy (HIPEC) has emerged as a potential treatment modality for patients with intra-abdominal metastatic colorectal cancer, especially peritoneal metastases that can be cured by a combination of cytoreductive surgery and perioperative HIPEC [<xref ref-type="bibr" rid="CR22">22</xref>]. Cytoreductive surgery and intraperitoneal hyperthermic chemotherapy (CRS-HIPEC) is increasingly being used to treat colorectal peritoneal metastasis (CPM). Significant learning curve (LC) improves perioperative outcomes after CRS-HIPEC for CPM [<xref ref-type="bibr" rid="CR23">23</xref>]. Total mesorectal excision, or TME, demonstrates the pivotal role of regional lymphadenectomy in the surgical treatment of colorectal cancer. It has been reported that paraaortic lymph node dissection (PLND) has become a potentially effective treatment strategy for isolated paraaortic lymph node metastasis (PLNM) [<xref ref-type="bibr" rid="CR24">24</xref>].</p><p id="Par30">The only effective strategy for the long-term survival of patients with colorectal cancer with local recurrence is early detection of local recurrence and curative treatment [<xref ref-type="bibr" rid="CR25">25</xref>]. Regardless of the advances in chemotherapy, the only cure for colorectal metastases is surgery, which necessitates complete resection from all metastatic sites [<xref ref-type="bibr" rid="CR26">26</xref>].</p><p id="Par31">This study has the following limitations. First, this study was a single-center retrospective study, which may have led to statistical bias in the results. Second, this study did not include cases of reoperation after recurrence. With the development of medical technology, patients with simple liver and lung metastases have recurrence and metastasis but can still achieve remission with surgical treatment. Third, this study did not include the palliative treatment plan and cycle of patients with unresectable metastatic rectal cancer, with or without standardized treatment and regular follow-up. Although various prognostic factors are present for patients with stage IV colorectal cancer, here, we included the maximum possible number of factors for a comprehensive analysis, and the results and conclusions of the analysis are credible.</p><p id="Par32">In conclusion, the prognosis of patients with metastases to the peritoneum and multiple organs is poor. The findings of this study suggests the need for the early monitoring of peritoneal and multiple organ or site recurrence after surgery. Patients with recurrent peritoneal and multiple organ/site metastasis should receive comprehensive treatment as early as possible to improve their prognosis. Actively communicating with patients and their relatives or administering intensive treatment is necessary.</p></sec></body><back><glossary><title>Abbreviations</title><def-list><def-item><term>PRS</term><def><p id="Par5">Post-recurrence surviva</p></def></def-item><def-item><term>lRFS</term><def><p id="Par6">Recurrence-free survival</p></def></def-item><def-item><term>CI</term><def><p id="Par7">Confidence interval</p></def></def-item><def-item><term>CRC</term><def><p id="Par8">Colorectal cancer</p></def></def-item><def-item><term>HR</term><def><p id="Par9">Hazard ratio</p></def></def-item><def-item><term>IQR</term><def><p id="Par10">Interquartile range</p></def></def-item><def-item><term>CEA</term><def><p id="Par11">Carcinoembryonic antigen</p></def></def-item><def-item><term>CA 19-9</term><def><p id="Par12">Carcinoma antigen 19&#8211;9</p></def></def-item></def-list></glossary><fn-group><fn><p><bold>Publisher's Note</bold></p><p>Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p></fn><fn><p>Hongjiang Pu, Yaxue Chen and Ruoxia Shen contributed equally to the work.</p></fn></fn-group><notes notes-type="author-contribution"><title>Authors&#8217; contributions</title><p>Conception and design: Yang GJ, Dong XX. Acquisition, analysis, or interpretation of data: Pu HJ, Shen RX,Zhang Y,Liu LZ. Drafting of the manuscript: Pu HJ, Chen YX. Critical revision of the manuscript for important intellectual content: Pu HJ, Yang GJ, Dong XX. Statistical analysis: Pu HJ, Chen YX,Yang D. Administrative, technical, or material support: Yang GJ, Dong XX. Study supervision: Pu HJ, Yang GJ, Dong XX. Final approval of the manuscript: all authors.</p></notes><notes notes-type="funding-information"><title>Funding</title><p>This study was supported by the Scientific research fund project of Yunnan Provincial Department of Education (2020J0208); Yunnan Fundamental Research Projects (grant NO. 202001AY070001-242&#65292;202001AY070001-240).</p></notes><notes notes-type="data-availability"><title>Availability of data and materials</title><p>Original data are available upon request to the corresponding author, Yang GJ.</p></notes><notes><title>Declarations</title><notes id="FPar1"><title>Ethics approval and consent to participate</title><p id="Par33">This study protocol was reviewed and approved by the Institutional Review Board of Yunnan Cancer Hospital (KY2019141) and conducted in accordance with the principles of the Declaration of Helsinki. Written informed consent was obtained from all patients.</p></notes><notes id="FPar2" notes-type="COI-statement"><title>Competing interests</title><p id="Par34">The authors declare no competing interests.</p></notes></notes><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fitzmaurice</surname><given-names>C</given-names></name><name name-style="western"><surname>Abate</surname><given-names>D</given-names></name><name name-style="western"><surname>Abbasi</surname><given-names>N</given-names></name><name name-style="western"><surname>Abbastabar</surname><given-names>H</given-names></name><name name-style="western"><surname>Abd-Allah</surname><given-names>F</given-names></name><name name-style="western"><surname>Abdel-Rahman</surname><given-names>O</given-names></name><etal/></person-group><article-title>Global, Regional, and National Cancer Incidence, Mortality, Years of Life Lost, Years Lived With Disability, and Disability-Adjusted Life-Years for 29 Cancer Groups, 1990 to 2017</article-title><source>JAMA Oncol</source><year>2019</year><volume>5</volume><issue>12</issue><fpage>1749</fpage><lpage>1769</lpage><pub-id pub-id-type="doi">10.1001/jamaoncol.2019.2996</pub-id><pub-id pub-id-type="pmid">31560378</pub-id><pub-id pub-id-type="pmcid">PMC6777271</pub-id></element-citation></ref><ref id="CR2"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>Z</given-names></name><name name-style="western"><surname>Li</surname><given-names>S</given-names></name><name name-style="western"><surname>Liang</surname><given-names>Y</given-names></name><name name-style="western"><surname>Pu</surname><given-names>H</given-names></name><name name-style="western"><surname>Tu</surname><given-names>C</given-names></name><name name-style="western"><surname>Wu</surname><given-names>Z</given-names></name><name name-style="western"><surname>You</surname><given-names>D</given-names></name></person-group><article-title>Predictive Value of Postoperative Peripheral CD4+ T Cells Percentage in Stage I-III Colorectal Cancer: A Retrospective Multicenter Cohort Study of 1028 Subjects</article-title><source>Cancer Manag Res</source><year>2020</year><volume>7</volume><issue>12</issue><fpage>5505</fpage><lpage>5513</lpage><pub-id pub-id-type="doi">10.2147/CMAR.S259464</pub-id><pub-id pub-id-type="pmcid">PMC7353995</pub-id><pub-id pub-id-type="pmid">32753965</pub-id></element-citation></ref><ref id="CR3"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pu</surname><given-names>H</given-names></name><name name-style="western"><surname>Xie</surname><given-names>P</given-names></name><name name-style="western"><surname>Chen</surname><given-names>Y</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>Y</given-names></name><name name-style="western"><surname>Ye</surname><given-names>X</given-names></name><name name-style="western"><surname>Lu</surname><given-names>G</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>D</given-names></name><name name-style="western"><surname>Li</surname><given-names>Z</given-names></name></person-group><article-title>Relationship Between Preoperative and Postoperative Serum Carcinoembryonic Antigen and Prognosis of Patients with Stage I-III Rectal Cancer: A Retrospective Study of a Multicentre Cohort of 1022 Rectal Cancer Patients</article-title><source>Cancer Manag Res</source><year>2021</year><volume>18</volume><issue>13</issue><fpage>2643</fpage><lpage>2651</lpage><pub-id pub-id-type="doi">10.2147/CMAR.S290416</pub-id><pub-id pub-id-type="pmcid">PMC7987265</pub-id><pub-id pub-id-type="pmid">33776482</pub-id></element-citation></ref><ref id="CR4"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Konishi</surname><given-names>T</given-names></name><name name-style="western"><surname>Shimada</surname><given-names>Y</given-names></name><name name-style="western"><surname>Hsu</surname><given-names>M</given-names></name><name name-style="western"><surname>Tufts</surname><given-names>L</given-names></name><name name-style="western"><surname>Jimenez-Rodriguez</surname><given-names>R</given-names></name><name name-style="western"><surname>Cercek</surname><given-names>A</given-names></name><name name-style="western"><surname>Yaeger</surname><given-names>R</given-names></name><name name-style="western"><surname>Saltz</surname><given-names>L</given-names></name><name name-style="western"><surname>Smith</surname><given-names>JJ</given-names></name><name name-style="western"><surname>Nash</surname><given-names>GM</given-names></name><name name-style="western"><surname>Guillem</surname><given-names>JG</given-names></name><name name-style="western"><surname>Paty</surname><given-names>PB</given-names></name><name name-style="western"><surname>Garcia-Aguilar</surname><given-names>J</given-names></name><name name-style="western"><surname>Gonen</surname><given-names>M</given-names></name><name name-style="western"><surname>Weiser</surname><given-names>MR</given-names></name></person-group><article-title>Association of Preoperative and Postoperative Serum Carcinoembryonic Antigen and Colon Cancer Outcome</article-title><source>JAMA Oncol</source><year>2018</year><volume>4</volume><issue>3</issue><fpage>309</fpage><lpage>315</lpage><pub-id pub-id-type="doi">10.1001/jamaoncol.2017.4420</pub-id><pub-id pub-id-type="pmid">29270608</pub-id><pub-id pub-id-type="pmcid">PMC5885834</pub-id></element-citation></ref><ref id="CR5"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hassett</surname><given-names>MJ</given-names></name><name name-style="western"><surname>Uno</surname><given-names>H</given-names></name><name name-style="western"><surname>Cronin</surname><given-names>AM</given-names></name><name name-style="western"><surname>Carroll</surname><given-names>NM</given-names></name><name name-style="western"><surname>Hornbrook</surname><given-names>MC</given-names></name><name name-style="western"><surname>Fishman</surname><given-names>P</given-names></name><name name-style="western"><surname>Ritzwoller</surname><given-names>DP</given-names></name></person-group><article-title>Survival after recurrence of stage I-III breast, colorectal, or lung cancer</article-title><source>Cancer Epidemiol</source><year>2017</year><volume>49</volume><fpage>186</fpage><lpage>194</lpage><pub-id pub-id-type="doi">10.1016/j.canep.2017.07.001</pub-id><pub-id pub-id-type="pmid">28710943</pub-id><pub-id pub-id-type="pmcid">PMC5572775</pub-id></element-citation></ref><ref id="CR6"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Safari</surname><given-names>M</given-names></name><name name-style="western"><surname>Mahjub</surname><given-names>H</given-names></name><name name-style="western"><surname>Esmaeili</surname><given-names>H</given-names></name><name name-style="western"><surname>Abbasi</surname><given-names>M</given-names></name><name name-style="western"><surname>Roshanaei</surname><given-names>G</given-names></name></person-group><article-title>Specific causes of recurrence after surgery and mortality in patients with colorectal cancer: A competing risks survival analysis</article-title><source>J Res Med Sci</source><year>2021</year><volume>27</volume><issue>26</issue><fpage>13</fpage><pub-id pub-id-type="doi">10.4103/jrms.JRMS_430_20.PMID:34084192;PMCID:PMC8106405</pub-id><pub-id pub-id-type="pmcid">PMC8106405</pub-id><pub-id pub-id-type="pmid">34084192</pub-id></element-citation></ref><ref id="CR7"><label>7.</label><element-citation publication-type="book"><person-group person-group-type="author"><collab>National-Comprehensive-Cancer-Network (NCCN)</collab></person-group><source>NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines): Colon Cancer. (Version 2.2020)</source><year>2020</year><publisher-loc>Fort Washington</publisher-loc><publisher-name>National Comprehensive Cancer Network</publisher-name></element-citation></ref><ref id="CR8"><label>8.</label><element-citation publication-type="book"><person-group person-group-type="author"><collab>National-Comprehensive-Cancer-Network (NCCN)</collab></person-group><source>NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines): Rectal Cancer. (Version 3.2020)</source><year>2020</year><publisher-loc>Fort Washington</publisher-loc><publisher-name>National Comprehensive Cancer Network</publisher-name></element-citation></ref><ref id="CR9"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>von Elm</surname><given-names>E</given-names></name><name name-style="western"><surname>Altman</surname><given-names>DG</given-names></name><name name-style="western"><surname>Egger</surname><given-names>M</given-names></name><name name-style="western"><surname>Pocock</surname><given-names>SJ</given-names></name><name name-style="western"><surname>G&#248;tzsche</surname><given-names>PC</given-names></name><name name-style="western"><surname>Vandenbroucke</surname><given-names>JP</given-names></name></person-group><article-title>STROBE Initiative. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) Statement: guidelines for reporting observational studies</article-title><source>Int J Surg</source><year>2014</year><volume>12</volume><issue>12</issue><fpage>1495</fpage><lpage>9</lpage><pub-id pub-id-type="doi">10.1016/j.ijsu.2014.07.013</pub-id><pub-id pub-id-type="pmid">25046131</pub-id></element-citation></ref><ref id="CR10"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sawayama</surname><given-names>H</given-names></name><name name-style="western"><surname>Miyamoto</surname><given-names>Y</given-names></name><name name-style="western"><surname>Hiyoshi</surname><given-names>Y</given-names></name><name name-style="western"><surname>Ogawa</surname><given-names>K</given-names></name><name name-style="western"><surname>Kato</surname><given-names>R</given-names></name><name name-style="western"><surname>Akiyama</surname><given-names>T</given-names></name><name name-style="western"><surname>Kiyozumi</surname><given-names>Y</given-names></name><name name-style="western"><surname>Yoshida</surname><given-names>N</given-names></name><name name-style="western"><surname>Baba</surname><given-names>H</given-names></name></person-group><article-title>Overall survival after recurrence in stage I-III colorectal cancer patients in accordance with the recurrence organ site and pattern</article-title><source>Ann Gastroenterol Surg</source><year>2021</year><volume>5</volume><issue>6</issue><fpage>813</fpage><lpage>822</lpage><pub-id pub-id-type="doi">10.1002/ags3.12483</pub-id><pub-id pub-id-type="pmid">34755013</pub-id><pub-id pub-id-type="pmcid">PMC8560596</pub-id></element-citation></ref><ref id="CR11"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wiesmueller</surname><given-names>F</given-names></name><name name-style="western"><surname>Schuetz</surname><given-names>R</given-names></name><name name-style="western"><surname>Langheinrich</surname><given-names>M</given-names></name><name name-style="western"><surname>Brunner</surname><given-names>M</given-names></name><name name-style="western"><surname>Weber</surname><given-names>GF</given-names></name><name name-style="western"><surname>Gr&#252;tzmann</surname><given-names>R</given-names></name><name name-style="western"><surname>Merkel</surname><given-names>S</given-names></name><name name-style="western"><surname>Krautz</surname><given-names>C</given-names></name></person-group><article-title>Defining early recurrence in patients with resected primary colorectal carcinoma and its respective risk factors</article-title><source>Int J Colorectal Dis</source><year>2021</year><volume>36</volume><issue>6</issue><fpage>1181</fpage><lpage>1191</lpage><pub-id pub-id-type="doi">10.1007/s00384-021-03844-7</pub-id><pub-id pub-id-type="pmid">33449131</pub-id><pub-id pub-id-type="pmcid">PMC8119399</pub-id></element-citation></ref><ref id="CR12"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Furuke</surname><given-names>H</given-names></name><name name-style="western"><surname>Arita</surname><given-names>T</given-names></name><name name-style="western"><surname>Kuriu</surname><given-names>Y</given-names></name><name name-style="western"><surname>Shimizu</surname><given-names>H</given-names></name><name name-style="western"><surname>Kiuchi</surname><given-names>J</given-names></name><name name-style="western"><surname>Yamamoto</surname><given-names>Y</given-names></name><name name-style="western"><surname>Konishi</surname><given-names>H</given-names></name><name name-style="western"><surname>Morimura</surname><given-names>R</given-names></name><name name-style="western"><surname>Shiozaki</surname><given-names>A</given-names></name><name name-style="western"><surname>Ikoma</surname><given-names>H</given-names></name><name name-style="western"><surname>Kubota</surname><given-names>T</given-names></name><name name-style="western"><surname>Nakanishi</surname><given-names>M</given-names></name><name name-style="western"><surname>Fujiwara</surname><given-names>H</given-names></name><name name-style="western"><surname>Okamoto</surname><given-names>K</given-names></name><name name-style="western"><surname>Otsuji</surname><given-names>E</given-names></name></person-group><article-title>The survival after recurrence of colorectal cancer: a retrospective study focused on time to recurrence after curative resection</article-title><source>Surg Today</source><year>2022</year><volume>52</volume><issue>2</issue><fpage>239</fpage><lpage>250</lpage><pub-id pub-id-type="doi">10.1007/s00595-021-02336-z</pub-id><pub-id pub-id-type="pmid">34269851</pub-id></element-citation></ref><ref id="CR13"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Robinson</surname><given-names>JR</given-names></name><name name-style="western"><surname>Newcomb</surname><given-names>PA</given-names></name><name name-style="western"><surname>Hardikar</surname><given-names>S</given-names></name><name name-style="western"><surname>Cohen</surname><given-names>SA</given-names></name><name name-style="western"><surname>Phipps</surname><given-names>AI</given-names></name></person-group><article-title>Stage IV colorectal cancer primary site and patterns of distant metastasis</article-title><source>Cancer Epidemiol</source><year>2017</year><volume>48</volume><fpage>92</fpage><lpage>95</lpage><pub-id pub-id-type="doi">10.1016/j.canep.2017.04.003</pub-id><pub-id pub-id-type="pmid">28437692</pub-id><pub-id pub-id-type="pmcid">PMC5592095</pub-id></element-citation></ref><ref id="CR14"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hugen</surname><given-names>N</given-names></name><name name-style="western"><surname>van de Velde</surname><given-names>CJH</given-names></name><name name-style="western"><surname>de Wilt</surname><given-names>JHW</given-names></name><name name-style="western"><surname>Nagtegaal</surname><given-names>ID</given-names></name></person-group><article-title>Metastatic pattern in colorectal cancer is strongly influenced by histological subtype</article-title><source>Ann Oncol</source><year>2014</year><volume>25</volume><issue>3</issue><fpage>651</fpage><lpage>657</lpage><pub-id pub-id-type="doi">10.1093/annonc/mdt591</pub-id><pub-id pub-id-type="pmid">24504447</pub-id><pub-id pub-id-type="pmcid">PMC4433523</pub-id></element-citation></ref><ref id="CR15"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>L</given-names></name><name name-style="western"><surname>Hirano</surname><given-names>Y</given-names></name><name name-style="western"><surname>Heng</surname><given-names>G</given-names></name><name name-style="western"><surname>Ishii</surname><given-names>T</given-names></name><name name-style="western"><surname>Kondo</surname><given-names>H</given-names></name><name name-style="western"><surname>Hara</surname><given-names>K</given-names></name><name name-style="western"><surname>Obara</surname><given-names>N</given-names></name><name name-style="western"><surname>Asari</surname><given-names>M</given-names></name><name name-style="western"><surname>Kato</surname><given-names>T</given-names></name><name name-style="western"><surname>Yamaguchi</surname><given-names>S</given-names></name></person-group><article-title>Does signet ring cell carcinoma component signify worse outcomes for patients with colorectal cancer?</article-title><source>Asian J Surg</source><year>2021</year><volume>44</volume><issue>1</issue><fpage>105</fpage><lpage>110</lpage><pub-id pub-id-type="doi">10.1016/j.asjsur.2020.03.017</pub-id><pub-id pub-id-type="pmid">32295719</pub-id></element-citation></ref><ref id="CR16"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Riihim&#228;ki</surname><given-names>M</given-names></name><name name-style="western"><surname>Hemminki</surname><given-names>A</given-names></name><name name-style="western"><surname>Sundquist</surname><given-names>J</given-names></name><name name-style="western"><surname>Hemminki</surname><given-names>K</given-names></name></person-group><article-title>Patterns of metastasis in colon and rectal cancer</article-title><source>Sci Rep</source><year>2016</year><volume>15</volume><issue>6</issue><fpage>29765</fpage><pub-id pub-id-type="doi">10.1038/srep29765</pub-id><pub-id pub-id-type="pmcid">PMC4945942</pub-id><pub-id pub-id-type="pmid">27416752</pub-id></element-citation></ref><ref id="CR17"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Amri</surname><given-names>R</given-names></name><name name-style="western"><surname>Bordeianou</surname><given-names>LG</given-names></name><name name-style="western"><surname>Sylla</surname><given-names>P</given-names></name><name name-style="western"><surname>Berger</surname><given-names>DL</given-names></name></person-group><article-title>Variations in Metastasis Site by Primary Location in Colon Cancer</article-title><source>J Gastrointest Surg</source><year>2015</year><volume>19</volume><issue>8</issue><fpage>1522</fpage><lpage>1527</lpage><pub-id pub-id-type="doi">10.1007/s11605-015-2837-9</pub-id><pub-id pub-id-type="pmid">25933582</pub-id></element-citation></ref><ref id="CR18"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Russolillo</surname><given-names>N</given-names></name><name name-style="western"><surname>Sperti</surname><given-names>E</given-names></name><name name-style="western"><surname>Langella</surname><given-names>S</given-names></name><name name-style="western"><surname>Menonna</surname><given-names>F</given-names></name><name name-style="western"><surname>Allieta</surname><given-names>A</given-names></name><name name-style="western"><surname>Di Maio</surname><given-names>M</given-names></name><name name-style="western"><surname>Ferrero</surname><given-names>A</given-names></name></person-group><article-title>Impact of primary tumor location on patterns of recurrence and survival of patients undergoing resection of liver metastases from colon cancer</article-title><source>HPB (Oxford)</source><year>2020</year><volume>22</volume><issue>1</issue><fpage>116</fpage><lpage>123</lpage><pub-id pub-id-type="doi">10.1016/j.hpb.2019.05.014</pub-id><pub-id pub-id-type="pmid">31235431</pub-id></element-citation></ref><ref id="CR19"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Le</surname><given-names>VH</given-names></name><name name-style="western"><surname>Thornblade</surname><given-names>L</given-names></name><name name-style="western"><surname>Ituarte</surname><given-names>PHG</given-names></name><name name-style="western"><surname>Lai</surname><given-names>LL</given-names></name><name name-style="western"><surname>Melstrom</surname><given-names>KA</given-names></name></person-group><article-title>Metachronous peritoneal metastases following curative resection for colon cancer: Understanding risk factors and patterns of recurrence</article-title><source>J Surg Oncol</source><year>2021</year><volume>123</volume><issue>2</issue><fpage>622</fpage><lpage>629</lpage><pub-id pub-id-type="doi">10.1002/jso.26322</pub-id><pub-id pub-id-type="pmid">33616972</pub-id></element-citation></ref><ref id="CR20"><label>20.</label><mixed-citation publication-type="other">Sugarbaker PH. Colorectal cancer: prevention and management of metastatic disease. Biomed Res Int. 2014;2014:782890. 10.1155/2014/782890. Epub 2014 Mar 24.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1155/2014/782890</pub-id><pub-id pub-id-type="pmcid">PMC3982272</pub-id><pub-id pub-id-type="pmid">24783222</pub-id></mixed-citation></ref><ref id="CR21"><label>21</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Matsui</surname><given-names>Y</given-names></name><name name-style="western"><surname>Hiraki</surname><given-names>T</given-names></name><name name-style="western"><surname>Gobara</surname><given-names>H</given-names></name><name name-style="western"><surname>Iguchi</surname><given-names>T</given-names></name><name name-style="western"><surname>Fujiwara</surname><given-names>H</given-names></name><name name-style="western"><surname>Nagasaka</surname><given-names>T</given-names></name><name name-style="western"><surname>Toyooka</surname><given-names>S</given-names></name><name name-style="western"><surname>Kanazawa</surname><given-names>S</given-names></name></person-group><article-title>Long-term survival following percutaneous radiofrequency ablation of colorectal lung metastases</article-title><source>J Vasc Interv Radiol.</source><year>2015</year><volume>26</volume><issue>3</issue><fpage>303</fpage><lpage>10</lpage><pub-id pub-id-type="doi">10.1016/j.jvir.2014.11.013</pub-id><pub-id pub-id-type="pmid">25612808</pub-id></element-citation></ref><ref id="CR22"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Klempner</surname><given-names>SJ</given-names></name><name name-style="western"><surname>Ryan</surname><given-names>DP</given-names></name></person-group><article-title>HIPEC for colorectal peritoneal metastases</article-title><source>Lancet Oncol</source><year>2021</year><volume>22</volume><issue>2</issue><fpage>162</fpage><lpage>164</lpage><pub-id pub-id-type="doi">10.1016/S1470-2045(20)30693-8</pub-id><pub-id pub-id-type="pmid">33476594</pub-id></element-citation></ref><ref id="CR23"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chidambarasamy</surname><given-names>ES</given-names></name><name name-style="western"><surname>Chia</surname><given-names>CS</given-names></name><name name-style="western"><surname>Johnny Ong</surname><given-names>CA</given-names></name><name name-style="western"><surname>Soo</surname><given-names>KC</given-names></name><name name-style="western"><surname>Ching Teo</surname><given-names>MC</given-names></name><name name-style="western"><surname>Ching Tan</surname><given-names>GH</given-names></name></person-group><article-title>Effect of the learning curve of cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) on the treatment of colorectal peritoneal metastasis</article-title><source>Asian J Surg</source><year>2022</year><volume>45</volume><issue>1</issue><fpage>339</fpage><lpage>345</lpage><pub-id pub-id-type="doi">10.1016/j.asjsur.2021.06.003</pub-id><pub-id pub-id-type="pmid">34148748</pub-id></element-citation></ref><ref id="CR24"><label>24.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sun</surname><given-names>KK</given-names></name><name name-style="western"><surname>Wu</surname><given-names>YY</given-names></name></person-group><article-title>Para-aortic lymph node dissection for colorectal cancer in the current era</article-title><source>Asian J Surg</source><year>2021</year><volume>44</volume><issue>7</issue><fpage>1019</fpage><lpage>1020</lpage><pub-id pub-id-type="doi">10.1016/j.asjsur.2021.04.038</pub-id><pub-id pub-id-type="pmid">34039472</pub-id></element-citation></ref><ref id="CR25"><label>25.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Papachristodoulou</surname><given-names>A</given-names></name><name name-style="western"><surname>Kouskos</surname><given-names>E</given-names></name><name name-style="western"><surname>Markopoulos</surname><given-names>C</given-names></name><name name-style="western"><surname>Karatzas</surname><given-names>G</given-names></name><name name-style="western"><surname>Kouraklis</surname><given-names>G</given-names></name><name name-style="western"><surname>Kostakis</surname><given-names>A</given-names></name></person-group><article-title>Local recurrence after radical surgery for colorectal cancer</article-title><source>Int Surg.</source><year>2002</year><volume>87</volume><issue>1</issue><fpage>19</fpage><lpage>24</lpage><pub-id pub-id-type="pmid">12144185</pub-id></element-citation></ref><ref id="CR26"><label>26.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Abdalla</surname><given-names>EK</given-names></name><name name-style="western"><surname>Adam</surname><given-names>R</given-names></name><name name-style="western"><surname>Bilchik</surname><given-names>AJ</given-names></name><name name-style="western"><surname>Jaeck</surname><given-names>D</given-names></name><name name-style="western"><surname>Vauthey</surname><given-names>JN</given-names></name><name name-style="western"><surname>Mahvi</surname><given-names>D</given-names></name></person-group><article-title>Improving resectability of hepatic colorectal metastases: expert consensus statement</article-title><source>Ann Surg Oncol</source><year>2006</year><volume>13</volume><issue>10</issue><fpage>1271</fpage><lpage>1280</lpage><pub-id pub-id-type="doi">10.1245/s10434-006-9045-5</pub-id><pub-id pub-id-type="pmid">16955381</pub-id></element-citation></ref></ref-list></back></article></pmc-articleset>